000134613 001__ 134613
000134613 005__ 20240424142035.0
000134613 0247_ $$2doi$$a10.1021/acs.nanolett.3c04947
000134613 0248_ $$2sideral$$a138303
000134613 037__ $$aART-2024-138303
000134613 041__ $$aeng
000134613 100__ $$0(orcid)0000-0002-1791-0188$$aBonet-Aleta, Javier$$uUniversidad de Zaragoza
000134613 245__ $$aNanoparticle-Catalyzed Transamination under Tumor Microenvironment Conditions: A Novel Tool to Disrupt the Pool of Amino Acids and GSSG in Cancer Cells
000134613 260__ $$c2024
000134613 5060_ $$aAccess copy available to the general public$$fUnrestricted
000134613 5203_ $$aCatalytic cancer therapy targets cancer cells by exploiting the specific characteristics of the tumor microenvironment (TME). TME-based catalytic strategies rely on the use of molecules already present in the TME. Amino groups seem to be a suitable target, given the abundance of proteins and peptides in biological environments. Here we show that catalytic CuFe2O4 nanoparticles are able to foster transaminations with different amino acids and pyruvate, another key molecule present in the TME. We observed a significant in cellulo decrease in glutamine and alanine levels up to 48 h after treatment. In addition, we found that di- and tripeptides also undergo catalytic transamination, thereby extending the range of the effects to other molecules such as glutathione disulfide (GSSG). Mechanistic calculations for GSSG transamination revealed the formation of an imine between the oxo group of pyruvate and the free −NH2 group of GSSG. Our results highlight transamination as alternative to the existing toolbox of catalytic therapies.
000134613 536__ $$9info:eu-repo/grantAgreement/ES/DGA/E07-23R$$9info:eu-repo/grantAgreement/EC/H2020/742684/EU/Catalytic Dual-Function Devices Against Cancer/CADENCE$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 742684-CADENCE$$9info:eu-repo/grantAgreement/ES/MICINN/IJC-2020-044217-I
000134613 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000134613 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000134613 700__ $$0(orcid)0000-0002-0769-7168$$aAlegre-Requena, Juan Vicente
000134613 700__ $$aMartin-Martin, Javier
000134613 700__ $$aEncinas-Gimenez, Miguel$$uUniversidad de Zaragoza
000134613 700__ $$aMartín-Pardillos, Ana$$uUniversidad de Zaragoza
000134613 700__ $$0(orcid)0000-0003-4160-9720$$aMartin-Duque, Pilar$$uUniversidad de Zaragoza
000134613 700__ $$0(orcid)0000-0002-4546-4111$$aHueso, Jose L.$$uUniversidad de Zaragoza
000134613 700__ $$0(orcid)0000-0002-8701-9745$$aSantamaria, Jesus$$uUniversidad de Zaragoza
000134613 7102_ $$11013$$2275$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Estomatología
000134613 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000134613 773__ $$g24, 14 (2024), 4091-4100$$pNano lett.$$tNano Letters$$x1530-6984
000134613 8564_ $$s6143885$$uhttps://zaguan.unizar.es/record/134613/files/texto_completo.pdf$$yVersión publicada
000134613 8564_ $$s2889066$$uhttps://zaguan.unizar.es/record/134613/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000134613 909CO $$ooai:zaguan.unizar.es:134613$$particulos$$pdriver
000134613 951__ $$a2024-04-24-13:24:35
000134613 980__ $$aARTICLE